Key result
In patients with Wolff-Parkinson-White syndrome undergoing accessory pathway ablation, the presence of Ebstein's anomaly did not affect 10-year survival.
Why the study?
Does the presence of Ebstein's anomaly affect the long-term outcomes of surgical ablation of accessory pathways in patients with Wolff-Parkinson-White syndrome?
Cohort (n=422)
Does the presence of Ebstein's anomaly affect the long-term outcomes of surgical ablation of accessory pathways in patients with Wolff-Parkinson-White syndrome?
Surgical ablation of accessory pathways in WPW patients with Ebstein's anomaly is safe and effective, yielding long-term survival and arrhythmia reduction comparable to patients without the anomaly.
Answers are grounded in this paper and cite their sources.
No survival difference with Ebstein's anomaly after WPW ablation; observational data leave open questions on arrhythmia recurrence and procedural risks.
BACKGROUND: Ebstein's anomaly is the most commonly occurring congenital abnormality associated with the Wolff-Parkinson-White (WPW) syndrome. However, the effects of Ebstein's anomaly on the risks and benefits of surgical ablation of accessory pathways in patients with WPW syndrome are unknown. METHODS AND RESULTS: This study compared the long-term outcome of 38 WPW patients with Ebstein's anomaly undergoing accessory pathway ablation to a reference population of 384 similarly treated patients without the anomaly. Ebstein's anomaly was mild in 21 patients (55%) and moderate-to-severe in 17 patients (45%). Sixteen patients (42%) required tricuspid valve surgery, and 23 (61%) had an atrial septal defect or patent foramen ovale repaired. Baseline clinical characteristics and preoperative clinical arrhythmias were similar in both groups. Ten-year survival was 92.4% and 91.2% for patients with and without Ebstein's anomaly, respectively (p = NS). During a mean follow-up of 6.2 +/- 3.8 and 5.3 +/- 3.6 years, 82% of patients with and 90% without Ebstein's anomaly had either clinically insignificant or no arrhythmias, and 18% versus 10% reported symptoms suggesting arrhythmias lasting longer than 1 minute, respectively. Atrial fibrillation was reduced postoperatively to 9% (p less than 0.001) in patients with and to 4% (p less than 0.001) in those without the anomaly. Fewer hospitalizations were reported postoperatively by 90% versus 96% of patients with and without Ebstein's anomaly; 9.4% versus 6.0% of patients were disabled at follow-up, respectively (p = NS). CONCLUSIONS: Patients with Ebstein's anomaly are improved significantly after accessory pathway ablation. The presence of this anomaly should not preclude accessory pathway ablation in these patients.
No takes yet. Share an insight, caveat, or question.
Pressley et al. (1992) conducted a cohort in Wolff-Parkinson-White syndrome (n=422). Ebstein's anomaly vs. Patients without Ebstein's anomaly was evaluated on Ten-year survival (p=NS). In patients with Wolff-Parkinson-White syndrome undergoing accessory pathway ablation, the presence of Ebstein's anomaly did not affect 10-year survival.
Synapse has enriched 10 related papers. Consider them for comparative context: